Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Programs
Patients and Physicians
Inside Seres
Open Positions
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Aug 03, 2021

Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

Jul 29, 2021

Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021

Jul 22, 2021

Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis

Jul 22, 2021

Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

Jul 01, 2021

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

Jun 10, 2021

Seres Therapeutics to Host Virtual Investor Event on June 21, 2021

Jun 10, 2021

Seres Therapeutics to Present at JMP Securities Life Sciences Conference

Jun 04, 2021

Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 01, 2021

Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)

May 25, 2021

Seres Therapeutics to Present at Upcoming Virtual Investor Conferences

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2021 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook